
Encore Medical, Inc.
EMIFiledEncore Medical, Inc. · Exchange pending · Research source · S-1/A · 2026-09-28 · Latest filing · S-1/A · 2026-11-16 SEC ↗
Encore Medical advances a conditional IPO while losses, liquidity needs, and regulatory execution remain material.
As of the September 28, 2026 S-1/A, Encore Medical proposed a $5.00 IPO for 3,000,000 shares, subject to completion and NYSE American listing.
- Business and development direction
Encore Medical, Inc.
Current business Future development
Key risks
Risk 1
The company has no U.S. marketing approval; failure or delay in the stroke trial and PMA process could prevent U.S. commercialization.
Risk 2
The auditor’s going-concern doubt and management’s need for additional equity financing create a material funding dependency.
Risk 3
Product liability events could cause legal costs, recalls, regulatory scrutiny and loss of physician or patient confidence.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio | Shares |
|---|---|---|---|---|
| 1 | The Oak Ridge Financial Services Group, Inc. | |||
| 2 | Network 1 Financial Securities, Inc. |
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $0.4 | $ / share |
| Total underwriting discount | $1,200,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 3; source 26516:33109; SHA256 6bcbb5c4822d303474cad878dc0eeda62042e9f2b94d1be414c834943c76a484 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 3; source 26516:33109; SHA256 6bcbb5c4822d303474cad878dc0eeda62042e9f2b94d1be414c834943c76a484 ↗IPO CAPITAL QUALITY
Basis and evidence
S-1/A · 2026-09-28
As of the September 28, 2026 S-1/A, Encore Medical proposed a $5.00 IPO for 3,000,000 shares, subject to completion and NYSE American listing.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Primary shares · Encore Medical, Inc. | 3,000,000 | Shares |
| Offering price | $5 | $ / share |
| Gross offering amount | $15,000,000 | $ |
Source and calculation
Shares sold by the issuer; base offering Reported inputs; each row retains its own source basis.
Shares sold by the issuer; base offering
Prospectus Summary ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 2; source 26516:33109; SHA256 6bcbb5c4822d303474cad878dc0eeda62042e9f2b94d1be414c834943c76a484 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 2; source 26516:33109; SHA256 6bcbb5c4822d303474cad878dc0eeda62042e9f2b94d1be414c834943c76a484 ↗Proceeds and intended uses
| Measure | Reported value | Unit |
|---|---|---|
| Issuer proceeds before expenses | $13,800,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 4; source 26516:33109; SHA256 6bcbb5c4822d303474cad878dc0eeda62042e9f2b94d1be414c834943c76a484 ↗Dilution and valuation
Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Post-offer shares · Encore Medical, Inc. | 10,743,425 | — | |
| Capitalization shares — actual | 5,867,425 | — | |
| Capitalization shares — pro forma | 6,743,425 | — | |
| Capitalization shares — pro forma as adjusted | 10,743,425 | — | |
| Post-offer shares — base/no option | 10,743,425 | — | |
| Post-offer shares — full option | 11,193,425 | — | |
| Offering price | — | $5 | |
| Gross offering amount | — | $15,000,000 | |
| Primary shares · Encore Medical, Inc. | 3,000,000 | — |
Basis and evidence ↗
Immediately after offering; no overallotment
Reported inputs; each row retains its own source basis.
Exact input · Primary shares · Encore Medical, Inc.: 3,000,000
Capitalization share count; source stage: actual; Common Stock, par value $.01 par value; 20,000,000 shares authorized, 5,867,425 shares issued and outstanding, actual; 6,743,425 shares issued and outstanding, pro forma; 10,743,425 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma; Common Stock, par value $.01 par value; 20,000,000 shares authorized, 5,867,425 shares issued and outstanding, actual; 6,743,425 shares issued and outstanding, pro forma; 10,743,425 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma as adjusted; Common Stock, par value $.01 par value; 20,000,000 shares authorized, 5,867,425 shares issued and outstanding, actual; 6,743,425 shares issued and outstanding, pro forma; 10,743,425 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock outstanding immediately after this offering; 10,743,425 shares, or 11,193,425 shares if the underwriters exercise the over-allotment option in full.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Exact input · Post-offer shares — base/no option: 10,743,425
Prospectus share summary; Common stock outstanding immediately after this offering; 10,743,425 shares, or 11,193,425 shares if the underwriters exercise the over-allotment option in full.; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Exact input · Offering price: $5
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Source inputs required
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
Source ↗Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-09-28
Relationship filters
Select for details · Encore Medical, Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Joseph A. MarinoBeneficial shares | 1,893,395 | — | — | Pre-Offering; Shares Owned |
| Joseph A. MarinoBeneficial shares | 1,893,395 | — | — | Post-Offering; Shares Owned |
| Peter M. BuonomoBeneficial shares | 200,000 | — | — | Pre-Offering; Shares Owned |
| Peter M. BuonomoBeneficial shares | 200,000 | — | — | Post-Offering; Shares Owned |
| Scott S. RobinsonBeneficial shares | 100,000 | — | — | Pre-Offering; Shares Owned |
| Scott S. RobinsonBeneficial shares | 100,000 | — | — | Post-Offering; Shares Owned |
| Christopher J. TurnbullBeneficial shares | 305,505 | — | — | Pre-Offering; Shares Owned |
| Christopher J. TurnbullBeneficial shares | 305,505 | — | — | Post-Offering; Shares Owned |
| Todd C. JohnsonBeneficial shares | 750,311 | — | — | Pre-Offering; Shares Owned |
| Todd C. JohnsonBeneficial shares | 750,311 | — | — | Post-Offering; Shares Owned |
| Executive Officers and Directors as a Group (6 persons)Beneficial shares | 3,249,211 | — | — | Pre-Offering; Shares Owned |
| Executive Officers and Directors as a Group (6 persons)Beneficial shares | 3,249,211 | — | — | Post-Offering; Shares Owned |
| Joseph A. MarinoBeneficial ownership | — | 24.4%Beneficial | — | Pre-Offering; Percent Owned |
| Joseph A. MarinoBeneficial ownership | — | 15.5%Beneficial | — | Post-Offering; Percent Owned |
| Peter M. BuonomoBeneficial ownership | — | 2.6%Beneficial | — | Pre-Offering; Percent Owned |
| Peter M. BuonomoBeneficial ownership | — | 1.6%Beneficial | — | Post-Offering; Percent Owned |
| Scott S. RobinsonBeneficial ownership | — | 1.3%Beneficial | — | Pre-Offering; Percent Owned |
| Scott S. RobinsonBeneficial ownership | — | 0.8%Beneficial | — | Post-Offering; Percent Owned |
| Christopher J. TurnbullBeneficial ownership | — | 3.9%Beneficial | — | Pre-Offering; Percent Owned |
| Christopher J. TurnbullBeneficial ownership | — | 2.5%Beneficial | — | Post-Offering; Percent Owned |
| Todd C. JohnsonBeneficial ownership | — | 9.7%Beneficial | — | Pre-Offering; Percent Owned |
| Todd C. JohnsonBeneficial ownership | — | 6.2%Beneficial | — | Post-Offering; Percent Owned |
| Executive Officers and Directors as a Group (6 persons)Beneficial ownership | — | 41.9%Beneficial | — | Pre-Offering; Percent Owned |
| Executive Officers and Directors as a Group (6 persons)Beneficial ownership | — | 27%Beneficial | — | Post-Offering; Percent Owned |
| our officers and directorsOwnership as disclosed | — | approximately 27.0%Beneficial | — | Source statement; approximately ; source predicate: will own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares), of which Mr. Marino, our Chairman and CEO, will own, when combined with family members’ ownership, approximately 15.5% of our outstanding common stock following comple; source scope: of our outstanding common stock based on the SEC’s beneficial ownership rules (assuming no exercise of the underwriters’ option to purchase additional shares), of which Mr; not an additive ownership partition |
| Mr. Marino — when combined with family members’ ownershipOwnership as disclosed | — | approximately 15.5%Beneficial | — | Source statement; approximately ; source predicate: will own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares); source scope: of our outstanding common stock following completion of the offering (assuming no exercise of the underwriters’ option to purchase additional shares); not an additive ownership partition |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding |
Source and calculation ↗
Exact source ownership column: Pre-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Shares Owned; source holder: Joseph A. Marino(1)
Exact source ownership column: Post-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Shares Owned; source holder: Joseph A. Marino(1)
Exact source ownership column: Pre-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Shares Owned; source holder: Peter M. Buonomo(2)
Exact source ownership column: Post-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Shares Owned; source holder: Peter M. Buonomo(2)
Exact source ownership column: Pre-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Shares Owned; source holder: Scott S. Robinson(3)
Exact source ownership column: Post-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Shares Owned; source holder: Scott S. Robinson(3)
Exact source ownership column: Pre-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Shares Owned; source holder: Christopher J. Turnbull(4)
Exact source ownership column: Post-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Shares Owned; source holder: Christopher J. Turnbull(4)
Exact source ownership column: Pre-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Shares Owned; source holder: Todd C. Johnson(5)
Exact source ownership column: Post-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Shares Owned; source holder: Todd C. Johnson(5)
Exact source ownership column: Pre-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Shares Owned; source holder: Executive Officers and Directors as a Group (6 persons)
Exact source ownership column: Post-Offering; Shares Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Shares Owned; source holder: Executive Officers and Directors as a Group (6 persons)
Exact source ownership column: Pre-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Percent Owned; source holder: Joseph A. Marino(1)
Exact source ownership column: Post-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Percent Owned; source holder: Joseph A. Marino(1)
Exact source ownership column: Pre-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Percent Owned; source holder: Peter M. Buonomo(2)
Exact source ownership column: Post-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Percent Owned; source holder: Peter M. Buonomo(2)
Exact source ownership column: Pre-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Percent Owned; source holder: Scott S. Robinson(3)
Exact source ownership column: Post-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Percent Owned; source holder: Scott S. Robinson(3)
Exact source ownership column: Pre-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Percent Owned; source holder: Christopher J. Turnbull(4)
Exact source ownership column: Post-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Percent Owned; source holder: Christopher J. Turnbull(4)
Exact source ownership column: Pre-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Percent Owned; source holder: Todd C. Johnson(5)
Exact source ownership column: Post-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Percent Owned; source holder: Todd C. Johnson(5)
Exact source ownership column: Pre-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Pre-Offering; Percent Owned; source holder: Executive Officers and Directors as a Group (6 persons)
Exact source ownership column: Post-Offering; Percent Owned; holders may overlap; not an additive partition
Raw source column: Post-Offering; Percent Owned; source holder: Executive Officers and Directors as a Group (6 persons)
Source statement; approximately ; source predicate: will own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares), of which Mr. Marino, our Chairman and CEO, will own, when combined with family members’ ownership, approximately 15.5% of our outstanding common stock following comple; source scope: of our outstanding common stock based on the SEC’s beneficial ownership rules (assuming no exercise of the underwriters’ option to purchase additional shares), of which Mr; not an additive ownership partition
Upon completion of this offering, our officers and directors collectively will own approximately 27.0% of our outstanding common stock based on the SEC’s beneficial ownership rules (assuming no exercise of the underwriters’ option to purchase additional shares), of which Mr. Marino, our Chairman and CEO, will own, when combined with family members’ ownership, approximately 15.5% of our outstanding common stock following completion of the offering (assuming no exercise of the underwriters’ option to purchase additional shares). As such, our officers and directors will have significant influence in determining the outcome of any matters submitted to shareholders for approval, including the election of directors and any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interests as a shareholder.
Source statement; approximately ; source predicate: will own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares); source scope: of our outstanding common stock following completion of the offering (assuming no exercise of the underwriters’ option to purchase additional shares); not an additive ownership partition
Upon completion of this offering, our officers and directors collectively will own approximately 27.0% of our outstanding common stock based on the SEC’s beneficial ownership rules (assuming no exercise of the underwriters’ option to purchase additional shares), of which Mr. Marino, our Chairman and CEO, will own, when combined with family members’ ownership, approximately 15.5% of our outstanding common stock following completion of the offering (assuming no exercise of the underwriters’ option to purchase additional shares). As such, our officers and directors will have significant influence in determining the outcome of any matters submitted to shareholders for approval, including the election of directors and any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interests as a shareholder.
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding
Holders of common stock have no preemptive, subscription, redemption or conversion rights. Cumulative voting for directors is not permitted, but the holders of common stock are entitled to one vote per share in all matters to be voted on by shareholders. Subject to the rights of the holders of any outstanding Preferred Stock, holders of common stock are entitled to receive dividends legally available therefore, when, as and if declared by the Board of Directors and, upon liquidation or dissolution of the Company, whether voluntary or involuntary, to share equally in the assets of the Company available for distribution to the shareholders. The Company has never paid a cash dividend on its common stock and does not intend to pay dividends in the foreseeable future. The Company’s present intention is to retain all future earnings for use in its business. All shares of common stock presently outstanding are fully paid and non-assessable. The Board of Directors is authorized to issue additional shares of common stock, but not to exceed the amount authorized by the Company’s Articles, and to issue options and warrants for the purchase of such shares, on such terms and conditions and for such consideration as the Board may deem appropriate without further shareholder action.
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| We and our executive officers, directors and shareholders holding 2% or more of the company’s outstanding common stockAfter date of this prospectus · Source conditions apply | 180 days |
Source and calculation
We and our executive officers, directors and shareholders holding 2% or more of the company’s outstanding common stock have agreed with the underwriters, subject to certain exceptions, not to sell or transfer any common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus (the “Restricted Period”), except with the prior written consent of the Representative.
SEC lock-up paragraph; source 1097674:1098374; SHA256 0d6ff8ed7d80495540627edf66928a4a90fa97f7504bc3be93108ee582447d0e ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of this prospectus
- We and our executive officers, directors and shareholders holding 2% or more of the company’s outstanding common stockWe and our executive officers, directors and shareholders holding 2% or more of the company’s outstanding common stock have agreed with the underwriters, subject to certain exceptions, not to sell or transfer any common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus (the “Restricted Period”), except with the prior written consent of the Representative.
| Holder / event | Term / date | Conditions |
|---|---|---|
| We and our executive officers, directors and shareholders holding 2% or more of the company’s outstanding common stock | 180 days | We and our executive officers, directors and shareholders holding 2% or more of the company’s outstanding common stock have agreed with the underwriters, subject to certain exceptions, not to sell or transfer any common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus (the “Restricted Period”), except with the prior written consent of the Representative. |
Basis and evidence
We and our executive officers, directors and shareholders holding 2% or more of the company’s outstanding common stock have agreed with the underwriters, subject to certain exceptions, not to sell or transfer any common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus (the “Restricted Period”), except with the prior written consent of the Representative.
SEC lock-up paragraph; source 1097674:1098374; SHA256 0d6ff8ed7d80495540627edf66928a4a90fa97f7504bc3be93108ee582447d0e ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Revenue
USD · Annual values as reportedNet income / (loss)
USD · Annual values as reportedOperating cash flow
USD · Annual values as reported| Calculation | FY2024 | FY2025 |
|---|---|---|
| Revenue | USD 2,134,528 | USD 2,585,858 |
| Net income / (loss) | (USD 1,845,951) | (USD 928,088) |
| Operating cash flow | (USD 462,270) | (USD 668,073) |
| Calculation | Reported value | Reference |
|---|---|---|
| Current assets2025-12-31 | USD 1,802,293 | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Current assets2024-12-31 | USD 1,010,463 | December 31, 2024; issuer; USD; as of 2024-12-31 |
| Total assets2025-12-31 | USD 2,160,381 | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Total assets2024-12-31 | USD 1,450,053 | December 31, 2024; issuer; USD; as of 2024-12-31 |
| Current liabilities2025-12-31 | USD 3,568,779 | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Current liabilities2024-12-31 | USD 1,011,277 | December 31, 2024; issuer; USD; as of 2024-12-31 |
| Total liabilities2025-12-31 | USD 3,830,090 | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Total liabilities2024-12-31 | USD 2,358,049 | December 31, 2024; issuer; USD; as of 2024-12-31 |
| Total equity / (deficit)2025-12-31 | (USD 1,669,709) | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Total equity / (deficit)2024-12-31 | (USD 907,996) | December 31, 2024; issuer; USD; as of 2024-12-31 |
| Current assets2026-06-30 · Unaudited | USD 1,472,257 | June 30, 2026; issuer unaudited; USD; as of 2026-06-30 |
| Current assets2025-12-31 · Unaudited | USD 1,802,293 | December 31, 2025; issuer unaudited; USD; as of 2025-12-31 |
| Total assets2026-06-30 · Unaudited | USD 1,786,441 | June 30, 2026; issuer unaudited; USD; as of 2026-06-30 |
| Total assets2025-12-31 · Unaudited | USD 2,160,381 | December 31, 2025; issuer unaudited; USD; as of 2025-12-31 |
| Current liabilities2026-06-30 · Unaudited | USD 3,846,347 | June 30, 2026; issuer unaudited; USD; as of 2026-06-30 |
| Current liabilities2025-12-31 · Unaudited | USD 3,568,779 | December 31, 2025; issuer unaudited; USD; as of 2025-12-31 |
| Total liabilities2026-06-30 · Unaudited | USD 4,060,291 | June 30, 2026; issuer unaudited; USD; as of 2026-06-30 |
| Total liabilities2025-12-31 · Unaudited | USD 3,830,090 | December 31, 2025; issuer unaudited; USD; as of 2025-12-31 |
| Total equity / (deficit)2026-06-30 · Unaudited | (USD 2,273,850) | June 30, 2026; issuer unaudited; USD; as of 2026-06-30 |
| Total equity / (deficit)2025-12-31 · Unaudited | (USD 1,669,709) | December 31, 2025; issuer unaudited; USD; as of 2025-12-31 |
| Revenue6M ended 2026-06-30 · Unaudited | USD 557,395 | 6M ended 2026-06-30; issuer unaudited; USD; 6 months ended 2026-06-30 |
| Revenue6M ended 2025-06-30 · Unaudited | USD 1,010,092 | 6M ended 2025-06-30; issuer unaudited; USD; 6 months ended 2025-06-30 |
| Net income / (loss)6M ended 2026-06-30 · Unaudited | (USD 610,965) | 6M ended 2026-06-30; issuer unaudited; USD; 6 months ended 2026-06-30 |
| Net income / (loss)6M ended 2025-06-30 · Unaudited | (USD 240,750) | 6M ended 2025-06-30; issuer unaudited; USD; 6 months ended 2025-06-30 |
| Operating cash flow6M ended 2026-06-30 · Unaudited | (USD 14,485) | 6M ended 2026-06-30; issuer unaudited; USD; 6 months ended 2026-06-30 |
| Operating cash flow6M ended 2025-06-30 · Unaudited | (USD 312,966) | 6M ended 2025-06-30; issuer unaudited; USD; 6 months ended 2025-06-30 |
Basis and evidence
Financial quality and runway
Financial quality and runway
Latest supplied period is the unaudited six months ended June 30, 2026. Revenue was $557,395 and net loss was $610,965. The filing also reports $79,771 cash and a substantial doubt regarding going concern; complete debt and operating-cash-flow amounts are not supplied in the excerpts.
EvidenceFinancial review 1Six-month 2026 revenue declined from $1,010,092 in the comparable six-month 2025 period in the supplied table.
+
Six-month 2026 revenue declined from $1,010,092 in the comparable six-month 2025 period in the supplied table.
EvidenceFinancial review 2The company reported a 2025 audited net loss of $928,088 and a six-month 2026 unaudited net loss of $610,965.
+
The company reported a 2025 audited net loss of $928,088 and a six-month 2026 unaudited net loss of $610,965.
EvidenceFinancial review 3The auditor’s 2025 report includes an explanatory paragraph raising substantial doubt about continuation for the following 12 months.
+
The auditor’s 2025 report includes an explanatory paragraph raising substantial doubt about continuation for the following 12 months.
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
No source-comparable material changes identified in this report.
S-1/A0001104659-26-111104 ↗
Loading filing history…
The company has no U.S. marketing approval; failure or delay in the stroke trial and PMA process could prevent U.S. commercialization.
- Evidence
- Risk Factors ↗
The auditor’s going-concern doubt and management’s need for additional equity financing create a material funding dependency.
- Evidence
- Risk Factors ↗
Product liability events could cause legal costs, recalls, regulatory scrutiny and loss of physician or patient confidence.
- Evidence
- Business ↗
The company faces competition from larger medical-device companies with greater financial, technical, regulatory and distribution resources.
- Evidence
- Business ↗